Literature DB >> 1884383

Immunotherapy and gene therapy of cancer.

S A Rosenberg1.   

Abstract

In the past decade, immunotherapies have been developed that are capable of causing prolonged cancer regressions in selected patients with advanced metastatic disease. In the past year, attempts at the gene therapy of cancer have begun. These experimental cancer treatments deserve vigorous exploration.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1884383

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  32 in total

1.  Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.

Authors:  Sid P Kerkar; Luis Sanchez-Perez; Shicheng Yang; Zachary A Borman; Pawel Muranski; Yun Ji; Dhanalakshmi Chinnasamy; Andrew D M Kaiser; Christian S Hinrichs; Christopher A Klebanoff; Christopher D Scott; Luca Gattinoni; Richard A Morgan; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunother       Date:  2011-05       Impact factor: 4.456

2.  Role of prolactin in the in vitro development of interleukin-2-driven anti-tumoural lymphokine-activated killer cells.

Authors:  L Matera; G Bellone; J J Lebren; P A Kelly; E L Hooghe Peters; P F Di Celle; R Foa; M Contarini; G Avanzi; V Asnaghi
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

3.  Mycoplasma arthritidis mitogen up-regulates human NK cell activity.

Authors:  J A D'Orazio; B C Cole; J Stein-Streilein
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

4.  Brain Tumor Working Group Report on the 9th International Conference on Brain Tumor Research and Therapy. Organ System Program, National Cancer Institute.

Authors:  D F Deen; A Chiarodo; E A Grimm; J R Fike; M A Israel; L E Kun; V A Levin; L J Marton; R J Packer; A E Pegg
Journal:  J Neurooncol       Date:  1993-06       Impact factor: 4.130

5.  Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.

Authors:  O Utermöhlen; C Schulze-Garg; G Warnecke; R Gugel; J Löhler; W Deppert
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

6.  Antiproliferative effect of polyunsaturated fatty acids and interleukin-2 on normal and abnormal human lymphocytes.

Authors:  M A Devi; N P Das
Journal:  Experientia       Date:  1994-05-15

Review 7.  New insights into tumor-host interactions in lymphoma metastasis.

Authors:  V Umansky; V Schirrmacher; M Rocha
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

8.  Relationship between immunological parameters and survival of patients with liver metastases from breast cancer given immuno-chemotherapy.

Authors:  S Yamasaki; N Kan; T Harada; Y Ichinose; Y Moriguchi; L Li; T Sugie; H Kodama; K Satoh; K Ohgaki
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

9.  Drug resistance in rat colon cancer cell lines is associated with minor changes in susceptibility to cytotoxic cells.

Authors:  W Van de Vrie; S A Van der Heyden; E E Gheuens; A M Bijma; E A De Bruijn; R L Marquet; A T Van Oosterom; A M Eggermont
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

Review 10.  From laboratory expertise to clinical practice: multidrug-resistance-based gene therapy becomes available for urologists.

Authors:  G H Mickisch; F H Schroeder
Journal:  World J Urol       Date:  1994       Impact factor: 4.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.